R-BRAVE (**R**are ***BRAF*** **V**ariant R**e**gistry Germany) / AIO-TF-0223

Multizentrische, retrospektive Erhebung von Patienten-Verläufen mit BRAF Non-V600-mutierten soliden Tumoren

STUDY TYPE	Retrospective registry
PROJECT LEAD / COORDINATION (YMO)	Dr. Alexej Ballhausen Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie | CVK Charité – Universitätsmedizin Berlin Augustenburger Platz 1 13353 Berlin alexej.ballhausen@charite.de Dr. Kathrin Heinrich Medizinische Klinik und Poliklinik III LMU Klinikum Marchioninistr. 15 81377 München Kathrin.Heinrich@med.uni-muenchen.de Dr. Sebastian Lange Klinik und Poliklinik für Innere Medizin II Klinikum rechts der Isar der TUM Ismaninger Straße 22 81675 München sebastian.lange@mri.tum.de Dr. Janna-Lisa Velthaus II. Medizinische Klinik und Poliklinik UKE Hamburg Martinistrasse 52 20246 Hamburg j.velthaus@uke.de
SCIENTIFIC CHAIRS	Prof. Dr. Tilman Brummer (Chair) Institute of Molecular Medicine and Cell Research University of Freiburg Stefan-Meier-Str. 17 79104 Freiburg Dr. Benedikt Westphalen (Co-Chair) Medizinische Klinik und Poliklinik III LMU Klinikum Marchioninistr. 15 81377 München

<table>
<tr><td>SENIOR ADVISORS</td><td>Prof. Dr. Annalen Bleckmann
Medizinische Klinik A
Universitätsklinikum Münster
Albert-Schweitzer-Campus 1, Gebäude A1
48149 Münster

Prof. Dr. Anna-Lena Illert
Klinikum rechts der Isar
Technische Universität München
Ismaninger Str. 22
81675 München

Prof. Dr. Dr. Sonja Loges
Universitätsmedizin Mannheim
Theodor-Kutzer-Ufer 1-3
68167 Mannheim</td></tr>
<tr><td>CONDITION</td><td>Advanced solid tumors after comprehensive molecular profiling</td></tr>
<tr><td>DESIGN</td><td>Retrospective</td></tr>
<tr><td>OBJECTIVE(S)</td><td>frequency of potentially clinically relevant non-V600E BRAF alterations including fusions/rearrangements
therapeutic recommendations for these alterations in molecular tumorboards
clinical outcome of patients with non-V600E BRAF alterations after being discussed in molecular tumorboards
clinical outcome of patients with non-V600E BRAF alterations receiving targeted treatment</td></tr>
<tr><td>INTERVENTION(S)</td><td>n/a</td></tr>
<tr><td>BACKROUND/RATIONALE</td><td>While BRAF V600E mutations are well described, the frequency and clinical relevance of non-V600E BRAF alterations remain unclear.

Here, we propose a retrospective registry of German molecular tumor board patients to characterize frequency and clinical relevance of non-V600E BRAF alterations.</td></tr>
<tr><td>COLLECTED DATA</td><td>Anonymized
Results of molecular profiling
Type of BRAF alteration
Somatic SNVs/Indels
Translocations
Optional: TMB/MSI
Patient data
Diagnosis (incl. Oncotree)
Age
Sex
MTB recommendation
Clinical follow-up after MTB
If treated with targeted therapy:
Response
Progression free survival
Overall survival</td></tr>
</table>

	▪ Documentation of pre- and post-targeted therapy ○ If not treated with targeted therapy: ▪ Overall survival
SAMPLE SIZE	Basic cohort: All patients discussed in molecular tumorboards in the participating centers. Study cohort: The study cohort is recruited out of the basic cohort and encloses only patients with BRAF alterations.
TRIAL DURATION	12 months
PARTICIPATING CENTERS	12
FURTHER CENTERS DESIRED?	yes
NUMBER of PATIENTS	To be determined
CURRENT NUMBER of PATIENTS	- Basic cohort: currently more than 11.000 patients discussed in the molecular tumor boards of participating centers - Study cohort: currently more than 550 patients with *BRAF* altered tumors, of which ~ 45% non-*BRAF* V600E